hepatitis B hyperimmune globulin

11/01/2000 - "Long-term immunoprophylaxis with hepatitis B immune globulin (HBIG) dramatically improved post-OLT survival, but recurrent HBV still occurred in up to 36% of the recipients. "
04/01/1982 - "Hepatitis B immune globulin (HBIG) is specific and effective for hepatitis B, but its value is offset by its high cost. "
08/01/2001 - "Long-term IV HBIG is effective in preventing recurrent hepatitis B. "
01/01/2013 - "  ETV combined with HBIG provides effective and safe prophylaxis in preventing hepatitis B recurrence after LDLT."
01/01/2014 - "Despite the success of postexposure prophylaxis (PEP) of the newborn in preventing mother-to-child transmission of hepatitis B virus), in non-US clinical trials, administering hepatitis B immune globulin (HBIG) to mothers at the end of pregnancy (in addition to passive-active PEP of the newborn) only partially improved outcomes. "

10/01/2013 - "In those non-immune patients exposed to HBV, the combination of HBIG plus vaccination provides the best protection against infection. "
01/01/2012 - "Successful clearance of HBV infection within 12 months was achieved in significantly more neonates in the HBIG adjusted therapy group than in the standard therapy group (82.8% vs. 57.4%; x2 = 9.696, P less than 0.05). "
12/01/2006 - "The addition of HBIG to recombinant vaccine will significantly increase the protection against HBV infection in comparison with HB vaccine alone."
06/01/2015 - "In this study, long-term outcome was evaluated in children with prenatal HBV infection who received the HBIG and HB vaccine in Japan. "
05/01/2002 - "Large controlled vaccination trials have revealed that HBV can be prevented by HBIg therapy in the majority of newborns after perinatal infection. "

09/01/1989 - "[Hepatitis B virus and epidemiological study on efficacy of HBIG and vaccine for the prevention of type B hepatitis after accidental exposures among medical staffs (2)]."
03/01/1987 - "[Hepatitis B virus and epidemiological study on efficacy of HBIG for the prevention of type B hepatitis after accidental exposures among medical staff]."
04/01/2012 - "Infantile fulminant hepatitis developed in 1 of 1050 children who did not receive HBIG (.095%). "
07/01/2007 - "Long-term low-dose IM and high-dose IV HBIG are equally efficacious with similar survival and early hepatitis recurrence rates. "
11/01/1985 - "This case illustrates the necessity for knowing the results of hepatitis serology before injection of HBIG is given in high risk individuals. "

10/01/1994 - "The importance of using critical ratio of HBIG and HBVac is indicated, and future application of this complex for vaccination of low- or nonresponders to the present HBVac, as well as for treatment of chronic hepatitis B patients is discussed."
02/01/2014 - "Compared with the control group, the incidence of HBV intrauterine infection (RR = 0.42, 95 % CI 0.27-0.64, P < 0.0001) and the number of chronic hepatitis B (CHB) infants (RR = 0.44, 95 % CI 0.32-0.61, P < 0.00001) were lower in the HBIG administration group. "
09/01/2011 - "For HBIG, 9.5 cases of chronic hepatitis B virus infections are prevented for each 100 pregnant women treated, with a cost-savings of $5,887 and 1.2 life-years gained per patient treated. "
09/01/2013 - "Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings."
05/01/2007 - "Before and after injection of three doses of HBIG, Serum HBV DNA levels were detected by fluorescence quantitative PCR in 10 non-pregnant and 23 pregnant women of chronic hepatitis B virus (HBV) carrier state. "

06/01/2015 - "In a large cohort of LDLT recipients for HBV-related liver disease, use of low-dose short-term HBIG with high genetic barrier drugs results in a substantially lower incidence of HBV recurrence, even in high-risk patients."
09/01/2013 - "Seventy-five of the 89 patients who underwent LRLT for HBV-related liver disease were not given HBIG. "
03/21/2006 - "To evaluate the long-term histological outcome of patients transplanted for HBV-related liver disease and given HBIg prophylaxis indefinitely after LT. "
08/01/2003 - "Twelve patients transplanted for HBV-related liver disease and treated with HBIg for at least 24 months were administered HBV vaccine (40 microg administered intramuscularly and repeated 1 and 2 months thereafter) 2 months after beginning the last HBIg dose. "
05/01/2009 - "In a recent study, a new intravenous HBIG, Niuliva has shown high efficacy in achieving protective anti-HBs levels after liver transplantation for HBV-related liver diseases, as well as a good safety profile. "